Cognitive & Neuropeptides · Source-reviewed dossier
VIP
Source-Reviewed Research Dossier
VIP is a 28-amino-acid endogenous neuropeptide that signals through VPAC receptors and participates in smooth-muscle, secretory, vascular and immune regulation. Therapeutic claims require route- and indication-specific evidence that is not supplied by general physiology.
Compound overview
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
- Product type
- Peptide research compound
- Catalog family
- VIP
- Research category
- Cognitive & Neuropeptides
- Catalog CAS RN
- 37221-79-7
- Catalog molecular formula
- C147H238N44O42S
- Catalog molecular weight
- 3325.85 g/mol
- Catalog sequence
- His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2
- Evidence status
- Established endogenous physiology with mainly preclinical therapeutic research
- Intended use
- Research, development and manufacturing use only
Literature reference parameters
- Compound or material class
- Vasoactive intestinal peptide / PACAP-receptor-family ligandCatalog-family identity
- Evidence scope
- Established endogenous physiology with mainly preclinical therapeutic researchDo not generalize beyond the cited model
- Source review
- Primary or authoritative records linked belowChecked 2026-09-01
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
How VIP is studied
A target-to-pathway view grounded in the linked research records.
Reported research findings
What published studies report about VIP
Reported outcomes are paired with their experimental model and evidence boundary.
VIP has pleiotropic immune functions
A review summarized VIP effects across innate and adaptive immune-cell pathways.
A mechanistic review does not establish efficacy for a supplied peptide material.
Read the primary studyIntestinal-radiation outcomes were preclinical
A 2024 study reported secretory-differentiation and injury outcomes in radiation-exposed intestinal models.
The model does not establish human treatment or catalog-lot quality.
Read the primary studyCatalog options
Variant specifications
Pack-level catalog data; lot-level controls remain document-specific.
Specification & documents for VIP5
Product specification
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Lot documentation
Request by lot: CoA, HPLC purity and MS identity
Specification & documents for VIP10
Product specification
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Lot documentation
Request by lot: CoA, HPLC purity and MS identity
Quality documentation
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Interpret the documents, not just the headline number.
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Research context
Published studies and regulatory records, not customer testimonials or usage guidance.
VIP has pleiotropic immune functions
A mechanistic review does not establish efficacy for a supplied peptide material.
View primary recordIntestinal-radiation outcomes were preclinical
The model does not establish human treatment or catalog-lot quality.
View primary recordCurated references
Third-party publications selected for direct relevance.
-
01
Immunology review
Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions
Review. 2013. PMID 22139413.
-
02
Animal injury model
VIP promotes secretory differentiation and mitigates radiation-induced intestinal injury
Preclinical study. 2024. PMID 39380035.
VIP questions
Concise answers for researchers comparing identity, evidence and catalog variants.
What is VIP?
VIP is a 28-amino-acid endogenous neuropeptide that signals through VPAC receptors and participates in smooth-muscle, secretory, vascular and immune regulation. Therapeutic claims require route- and indication-specific evidence that is not supplied by general physiology.
What evidence is available for VIP?
The evidence base is broad in physiology but therapeutic intervention evidence remains indication-specific and frequently preclinical.
Does the cited research validate this catalog material?
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
Which quality documents can be requested?
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
How should VIP be stored?
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge tools
Continue with structured evidence
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Ready to request a quote?
Selected: VIP5 · 5 mg × 10 vials